ReShape Lifesciences reported a weak top-line result for QQ1 2024 as revenue declined 15.0 YoY to 1.944 million, with a gross margin near 60% (0.60) driven by overhead reductions. The quarterly operating loss widened to 2.21 million, with net loss of 2.19 million and an EPS of -5.42. Management responded with a bold cost discipline plan that targets roughly 8 million in operating expense reductions for 2024, reflecting more than a 50% cut versus 2023, excluding one-time costs. This restructuring, together with the limited launch momentum for Lap-Band 2.0 FLEX and ongoing M&A diligence, is aimed at extending the company s cash runway and positioning RSLS for a path to profitability as the commercialization push accelerates. A key near-term driver is the full US launch of Lap-Band 2.0 FLEX expected in 2024, supported by a digital lead-generation strategy and a revamped patient engagement platform. While the GLP-1 weight-loss market provides meaningful tailwinds for demand in obesity treatment, it also creates structural headwinds for traditional bariatric devices as GLP-1 adoption reduces short-term procedure volumes. The balance sheet remains liquidity-positive with cash of 2.48 million against debt of 0.24 million, yielding a net debt position of -2.24 million and a current ratio of 2.24, underscoring a modestly leveraged profile that requires continued working-capital discipline. Overall, RSLS faces a crisp near-term profitability challenge but possesses a credible growth runway through Lap-Band 2.0 FLEX and strategic cost controls.”,